Fused compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor
CA 2526872 C · Owner: Abbott Laboratories · Inventors: Leanna, Robert M.; Koenig, John R.; Lukin, Kirill
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention discloses novel compounds of general formula (I) or a , pharmaceutically acceptable salt or prodrug thereof (in which X1 - X5 R5 - , R8b, Z1 - Z2 and Ar1 are defined herein) a method for inhibiting the VR1 , receptor in mammals using these compounds a method for controlling pain in , mammals and pharmaceutical compositions including those compounds and a process for making those compounds.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 10, 2004 and granted February 5, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended June 10, 2024.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 10, 2026.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.